Premium
Response of hepatitis B virus to antiretroviral treatment containing lamivudine in HBsAg‐positive and HBsAg‐negative HIV‐positive South African adults
Author(s) -
Singh Lanish,
Bell Trevor Graham,
Yousif Mukhlid,
Kramvis Anna
Publication year - 2019
Publication title -
journal of medical virology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.782
H-Index - 121
eISSN - 1096-9071
pISSN - 0146-6615
DOI - 10.1002/jmv.25375
Subject(s) - lamivudine , hbsag , virology , hepatitis b virus , medicine , human immunodeficiency virus (hiv) , hepatitis b , virus
Both hepatitis B virus (HBV) and human immunodeficiency virus (HIV) infection are highly endemic in sub‐Saharan Africa. This study examined serological and clinical follow‐up data from 39 HBV DNA‐positive, HIV‐positive black South African adults, who returned for follow‐up at 3, 6, 12, and 18 months post‐initiation of antiretroviral therapy (ART). Of the 39 participants, 10 experienced full suppression of HBV and 29 experienced no suppression, with 10 of these showing a virological breakthrough. All 10 patients who fully suppressed were HBsAg‐negative, with 16 of the 29 who did not suppress being HBsAg‐positive and 13 HBsAg‐negative ( P < 0.05). Participants fully suppressing the virus had significantly lower aminotransferase levels and were all HBsAg‐negative compared to those who did not suppress ( P < 0.05). HBV viral loads between HBsAg‐positive and HBsAg‐negative samples were similar at baseline and at the final time‐point. In these South African patients with HBV/HIV coinfection, HBsAg‐negative status at baseline was a predictor of the outcome of HBV suppression in response to ART containing lamivudine.